{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:16:30Z","timestamp":1791476190615,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","award":["BT\/IAEC\/2019\/04"],"award-info":[{"award-number":["BT\/IAEC\/2019\/04"]}],"id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003511","name":"Indian Institute of Technology Roorkee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003511","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ijantimicag.2020.106022","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T06:35:34Z","timestamp":1589870134000},"page":"106022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Assessment of polymyxin B\u2013doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia"],"prefix":"10.1016","volume":"56","author":[{"given":"Amit","family":"Gaurav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balram Ji","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Pathania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106022_bib0001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1086\/653053","article-title":"Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"51","author":"Jones","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0002","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0003","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1378\/chest.10-0166","article-title":"Pneumonia due to Pseudomonas aeruginosa part I: epidemiology, clinical diagnosis, and source","volume":"139","author":"Fujitani","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0005","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0007","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/cid\/ciu866","article-title":"Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections","volume":"60","author":"Pena","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0009","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/ajrccm.165.7.2105078","article-title":"Ventilator-associated pneumonia","volume":"165","author":"Chastre","year":"2002","journal-title":"Am J Respir Crit Care"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1164\/rccm.201011-1894OC","article-title":"Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa","volume":"184","author":"Lu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0011","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/ALN.0b013e31827515de","article-title":"Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"117","author":"Lu","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0012","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1128\/AAC.03064-15","article-title":"Clinical efficacy of polymyxin monotherapy versus nonvalidated polymyxin combination therapy versus validated polymyxin combination therapy in extensively drug-resistant Gram-negative bacillus infections","volume":"60","author":"Cai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00028-18","article-title":"Polymyxin B in combination with enrofloxacin exerts synergistic killing against extensively drug-resistant Pseudomonas aeruginosa","volume":"62","author":"Lin","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0014","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/CMR.00058-14","article-title":"Antimicrobial heteroresistance: an emerging field in need of clarity","volume":"28","author":"El-Halfawy","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0016","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0017","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijantimicag.2008.02.003","article-title":"Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?","volume":"32","author":"Ludlam","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0018","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1093\/jac\/dky306","article-title":"Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?","volume":"73","author":"Russell","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0019","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1086\/586749","article-title":"The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy","volume":"46","author":"Charles","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1476-9255-9-31","article-title":"Doxycycline impairs neutrophil migration to the airspaces of the lung in mice exposed to intratracheal lipopolysaccharide","volume":"9","author":"Moon","year":"2012","journal-title":"J Inflamm"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0021","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.pupt.2006.08.006","article-title":"Doxycycline attenuated lung injury by its biological effect apart from its antimicrobial function","volume":"20","author":"Fujita","year":"2007","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0022","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s10096-012-1680-0","article-title":"Oral doxycycline for non-systemic urinary tract infections (UTIs) due to P. aeruginosa and other Gram-negative uropathogens","volume":"31","author":"Cunha","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0023","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nchembio.559","article-title":"Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy","volume":"7","author":"Ejim","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s11274-013-1252-1","article-title":"Doxycycline interferes with quorum sensing-mediated virulence factors and biofilm formation in Gram-negative bacteria","volume":"29","author":"Husain","year":"2013","journal-title":"World J Microbiol Biotechnol"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0026","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/infdis\/jix139","article-title":"Hypoxia reduces the pathogenicity of Pseudomonas aeruginosa by decreasing the expression of multiple virulence factors","volume":"215","author":"Schaible","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0027","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled antibiotics for Gram-negative respiratory infections","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0028","first-page":"e00211","article-title":"Aerosolized polymyxin B for treatment of respiratory tract infections: determination of pharmacokinetic\u2013pharmacodynamic indices for aerosolized polymyxin B against Pseudomonas aeruginosa in a mouse lung infection model","volume":"61","author":"Lin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0029","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/AAC.01705-13","article-title":"Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration","volume":"58","author":"Yapa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0030","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.30.6.562","article-title":"Consensus summary of aerosolized antimicrobial agents: application of guideline criteria","volume":"30","author":"Le Le","year":"2010","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/jsre.2001.6227","article-title":"Lipopolysaccharide: neutralization by polymyxin B shuts down the signaling pathway of nuclear factor kappaB in peripheral blood mononuclear cells, even during activation","volume":"100","author":"Tsuzuki","year":"2001","journal-title":"J Surg Res"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0032","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1080\/21505594.2018.1449508","article-title":"Pyoverdine, a siderophore from Pseudomonas aeruginosa, translocates into C. elegans, removes iron, and activates a distinct host response","volume":"9","author":"Kang","year":"2018","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0033","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3389\/fmicb.2019.02048","article-title":"Pyoverdine-dependent virulence of Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"10","author":"Kang","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0034","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tim.2006.11.004","article-title":"Pyoverdine siderophores: from biogenesis to biosignificance","volume":"15","author":"Visca","year":"2007","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40262-015-0250-x","article-title":"Clinical pharmacokinetics of inhaled antimicrobials","volume":"54","author":"Stockmann","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0036","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1469-0691.2000.00058-2.x","article-title":"Pharmacodynamics of doxycycline","volume":"6","author":"Cunha","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0037","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/jac\/dkh435","article-title":"Post-antibiotic effect induced by an antibiotic combination: influence of mode, sequence and interval of exposure","volume":"54","author":"Li","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0038","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1128\/AAC.05298-11","article-title":"Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"55","author":"Bergen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0039","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jac\/dkx399","article-title":"Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model","volume":"73","author":"Cai","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106022_bib0040","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.05996-11","article-title":"In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae isolates","volume":"56","author":"Vidaillac","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920301850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:32:54Z","timestamp":1735673574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920301850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0924857920301850"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106022","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of polymyxin B\u2013doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106022"}}